title: Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands.
authors.affiliation: a Department of Clinical Oncology , Leiden University Medical Center , Leiden , The Netherlands.
authors.forename: M K
authors.initials: MK
authors.lastname: van der Kooij
authors.affiliation: a Department of Clinical Oncology , Leiden University Medical Center , Leiden , The Netherlands.
authors.forename: A
authors.initials: A
authors.lastname: Joosse
authors.affiliation: a Department of Clinical Oncology , Leiden University Medical Center , Leiden , The Netherlands.
authors.forename: F M
authors.initials: FM
authors.lastname: Speetjens
authors.affiliation: b Department of Medical Oncology , University Medical Center Groningen , Groningen , The Netherlands.
authors.forename: G A P
authors.initials: GA
authors.lastname: Hospers
authors.affiliation: b Department of Medical Oncology , University Medical Center Groningen , Groningen , The Netherlands.
authors.forename: C
authors.initials: C
authors.lastname: Bisschop
authors.affiliation: c Department of Medical Oncology , Isala , Zwolle , The Netherlands.
authors.forename: J W B
authors.initials: JW
authors.lastname: de Groot
authors.affiliation: d Department of Medical Oncology , Radboud University Medical Center , Nijmegen , The Netherlands.
authors.forename: R
authors.initials: R
authors.lastname: Koornstra
authors.affiliation: e Department of Medical Oncology , Netherlands Cancer Institute (NKI-AVL) , Amsterdam , The Netherlands.
authors.forename: C U
authors.initials: CU
authors.lastname: Blank
authors.affiliation: a Department of Clinical Oncology , Leiden University Medical Center , Leiden , The Netherlands.
authors.forename: E
authors.initials: E
authors.lastname: Kapiteijn
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000453:epidemiology / Q000556:secondary; D008875:Middle Aged; D009367:Neoplasm Staging; D009426:Netherlands / Q000453:epidemiology; D000077594:Nivolumab; D011379:Prognosis; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors / Q000276:immunology*; D015996:Survival Rate; D014604:Uveal Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000556:secondary; D000098943:Uveal Melanoma
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab; C582435:pembrolizumab